Search PubMed⌕ Search

Biomedical subjects

K C Rice

Publications and source records attributed to K C Rice.

At least 343 records · Page 19Linked to original sources
PubMed1984

Morphine noncompetitively inhibits [3H]leucine enkephalin binding to membranes lacking type-II delta binding sites: evidence for a two-site allosteric model.

Using the site-directed, delta-selective alkylating agent FIT (Rice et al., Science 220, 314-316, 1983), membranes devoid of detectable higher affinity delta binding sites were prepared. As compared to control membranes, the IC50 of morphine required to inhibit [3H]LE binding to FIT-treated membranes was two orders of magnitude lower. Further, morphine was a noncompetitive inhibitor of [3H]LE binding to FIT-treated membranes, supporting the notion that the lower affinity delta binding site is the delta binding site of the opiate receptor complex.

Allosteric Regulation↗
PubMed1984

Ionic conditions differentially affect 3H-DADL binding to type-I and type-II opiate delta receptors in vitro.

It is widely accepted that the prototypic delta agonist DADL (D-ala2-D-leu5-enkephalin) labels two binding sites in vitro. Using the site directed, receptor selective alkylating agents, BIT and FIT (Rice et al.. Science 220:314-316, 1983), we recently described (Rothman et al, Neuropeptides, in press) the preparation of membranes possessing only lower affinity 3H-DADL binding sites (FIT-treated membranes, type-I delta sites) as well as membranes greatly enriched with higher affinity binding sites (BIT-treated membranes, type-II delta sites). In this paper we report that ionic conditions differentially affect the binding of 3H-DADL to FIT- and BIT-treated membranes, supporting the notion that 3-H-DADL labels two distinct delta binding sites.

Animals↗
PubMed1984

Probes for narcotic receptor mediated phenomena. 7. Synthesis and pharmacological properties of irreversible ligands specific for mu or delta opiate receptors.

Syntheses of affinity reagents for opiate receptors based on the fentanyl, endo-ethenotetrahydrooripavine, and etonitazene carbon-nitrogen skeletons are described. The isothiocyanate, bromoacetamido, and methylfumaramido alkylating functions were employed in these compounds, some of which had previously been shown to be mu specific (12, BIT) and delta specific (8, FIT and 19, FAO) in vitro. Antinociceptive activity of the title compounds was determined in the mouse hot-plate test, which revealed that certain compounds in each class showed morphine-like activity. The binding EC50 values against [3H]Dalamid for opiate receptors in NG108-15 (delta receptors) and rat brain membranes (mu + delta receptors) are also reported. With this type of experiment, it was possible to independently measure the apparent affinity of the etonitazene congeners 12-14 for the mu and delta receptors.

Animals↗
PubMed1983

Calcium ion dependent covalent modification of calmodulin with norchlorpromazine isothiocyanate.

Calmodulin forms a covalent, one to one, complex with 3H-labeled norchlorpromazine isothiocyanate. Complex formation was monitored by high-performance liquid chromatography using a CN reverse-phase column which resolves calmodulin, the calmodulin-norchlorpromazine adduct, and norchlorpromazine isothiocyanate. Formation of the adduct requires Ca2+ and is not observed with norchlorpromazine. The one to one calmodulin-norchlorpromazine complex does not activate phosphodiesterase but can interact with the enzyme and competitively inhibit its stimulation by calmodulin. High concentrations of trifluoperazine inhibit whereas low concentrations stimulate complex formation. This apparent potentiation of the interaction of calmodulin with norchlorpromazine by another phenothiazine suggests that calmodulin contains at least two phenothiazine binding sites and that the binding of phenothiazine to calmodulin is cooperative.

Animals↗
PubMed1983

Effects of phencyclidine on rat prolactin, dopamine receptor and locomotor activity.

Plasma prolactin (PRL) was decreased in naive rats sacrificed 30 min after phencyclidine (PCP) administration (10 mg/kg, s.c.). There was, however, no decrease in plasma PRL 30 min after s.c. injection of PCP (10 mg/kg) on the 29th day following 28 days of chronic PCP administration. These data suggest the development of tolerance to the PRL-suppressive effect of PCP as result of long-term administration of the drug. The Bmax of [3H]-spiperone binding to rat striatal membranes was decreased 24 hrs after 28 days of PCP treatment without change in affinity (Kd). No indication of the development of tolerance in these rats was found with regard to the locomotor-stimulating effect of PCP. The plasma PRL-suppressive effect of the PCP analog PCMP was found to be stereospecific; (-) PCMP was much less potent than (+)-PCMP.

Animals↗
PubMed1983

Irreversible ligands with high selectivity toward delta and mu opiate receptors.

Alkylating agents that display strong selectivity for opiate receptor types delta or mu were prepared by appropriate modification of the structures of the strong analgesics fentanyl, etonitazene, and endoethenotetrahydrooripavine. The availability of these substances should facilitate studies of the structural basis of receptor specificity and of the physiologic roles of these receptors.

Alkylation↗
PubMed1983

Probes for narcotic receptor mediated phenomena. 5. Narcotic antagonist irreversible ligands based on endoethenotetrahydrooripavine.

Nine new compounds have been synthesized as potential affinity ligands for specific opioid receptors. The biochemical properties of three of these compounds were examined in detail and one of them, N-cyclopropylmethyl-7 alpha-methylfumaroylamido-6, 14-endoethenotetrahydronororipavine (NIH 10236), was found to be a potent irreversible ligand for the delta opioid receptor. It had the properties of a narcotic antagonist, as determined by its effect on adenylate cyclase activity of NG108-15 neuroblastoma-glioma cell homogenates. It is, thus, the first delta specific alkylating ligand known which is a narcotic antagonist. A second compound, the N-cyclopropylmethyl-7 alpha-isothiocyanato-6, 14-endoethenotetrahydronororipavine (NIH 10235) was found to be a mu specific alkylating ligand in brain and a reversible antagonist in the NG108-15 cells.

Animals↗
PubMed1983

Cardiovascular and plasma prolactin responses to stereoisomers of phencyclidine.

The effect of phencyclidine (PCP) and dextro- and levorotatory isomers of its derivatives 1-(1-phenylcyclo-hexyl)-3-methylpiperidine [(+)-PCMP and (-)-PCMP] (5 mg/kg, SC) on blood pressure (BP), heart rate (HR) and plasma prolactin (PRL) were examined. PCP and (+)-PCMP but not (-)-PCMP increased BP and HR and suppressed plasma PRL.

Animals↗
PubMed1983

Synthesis and pharmacological characterization of (+/-)-5,9 alpha-dimethyl-2-[2-(4-fluorophenyl)ethyl]-2'-hydroxy-6,7-benzomorphan (fluorophen), a ligand suitable for visualization of opiate receptors in vivo.

A fluorinated derivative of the benzomorphan opiate agonist phenazocine, (+/-)-5,9 alpha-dimethyl-2-[2-(4-fluorophenyl)ethyl]-2'-hydroxy-6, 7-benzomorphan (fluorophen), was prepared by N-acylation of (+/-)-5,9 alpha-dimethyl-2'-hydroxybenzomorphan with (p-fluorophenyl)acetyl chloride, followed by diborane reduction of the resulting amide. Fluorination produces only a twofold opiate receptor affinity loss when measured either by bioassay or receptor binding (selectivity mu congruent to delta greater than kappa). Labeled with 18F, fluorophen should be sufficiently potent to be useful as an in vivo probe for visualizing opiate receptors by positron emission transaxial tomography (PETT).

Animals↗
PubMed1982

Identification of a Mr 58 000 glycoprotein subunit of the opiate receptor.

A Mr 58 000 subunit of the opiate receptor has been identified using tritiated fentanyl isothiocyanate, a potent opiate alkylating reagent with specificity for the delta-opiate receptor subclass. The subunit is alkylated in the presence of dextrorphan but not levorphanol. The specifically labelled protein was retained on columns of immobilized wheat germ agglutinin and is therefore presumably a glycoprotein. Partial purification of the Mr 58 000 opiate receptor subunit from neuroblastoma X glioma NG108-15 hybrid cell membranes is described.

Animals↗
PubMed1982

Interaction of barbiturates with benzodiazepine receptors in the central nervous system.

The interaction of barbiturates with benzodiazepine receptors was studied in extensively washed membrane preparations from rat brain. Sedative/hypnotic and anesthetic barbiturates such as pentobarbital, and convulsant barbiturates such as DMBB, enhanced [3H]diazepam binding in a stereospecific fashion. Freeze-thawing of membranes resulted in a decrease in the potency of barbiturates to enhance [3H]diazepam binding, while the maximum response to barbiturates remained unchanged. Significant differences in both the potency and maximum enhancement of [3H]diazepam binding by pentobarbital was observed among brain regions. The rank order potency of pentobarbital in different brain regions was: cerebellum greater than cortex greater than hippocampus, while the rank order efficacy of pentobarbital in these brain regions was reversed. The effects of a combination of anesthetic and/or convulsant barbiturates on [3H]diazepam binding suggested that these compounds function as partial agonists while a combination of anesthetic or convulsant barbiturates with phenobarbital suggested that latter compound antagonized the actions of both anesthetic and convulsant barbiturates. The convulsant benzodiazepine Ro-5-3663 and inosine were more potent as inhibitors of pentobarbital-enhanced than basal (non-pentobarbital enhanced) [3H]diazepam binding. Solubilization of benzodiazepine receptors with Lubrol-PX resulted in a complete loss of barbiturate enhanced [3H]diazepam binding, and greater than a 75% loss in efficacy in the remaining (insoluble receptor) tissue. These data, coupled with recent observations from this and other laboratories, suggests that the site(s) at which barbiturates act to enhance [3H]diazepam binding to benzodiazepine receptors is distinct from the site at which GABA acts to enhance [3H]diazepam binding. The phenomenon of enhanced benzodiazepine binding by barbiturates may be related to the depressant actions of the barbiturates, that is, their direct effects to increase chloride conductance. Although it is premature to assign a pharmacologic correlate to this neurochemical phenomenon, it appears that this action may be related to the anesthetic effects of the barbiturates. However, the definitive assignment of either the electrophysiologic or pharmacologic sequelae to this neurochemical action will require further investigation.

Animals↗
PubMed1982

Nitroimipramines - synthesis and pharmacological effects of potent long-acting inhibitors of [3H] serotonin uptake and [3H] imipramine binding.

A series of nitro derivatives of imipramine have been prepared by nitration of imipramine. Several of the products, especially 2-nitroimipramine (2) and 2,8-dinitro-imipramine (4) were found to be very potent inhibitors of [3H] serotonin uptake and high affinity [3H]imipramine binding in human platelets. In contrast to the parent antidepressant, imipramine, the inhibition of platelet [3H] serotonin uptake and [3H] imipramine binding by the nitro derivatives of imipramine was long-acting and essentially irreversible at low temperatures. These compounds should prove to be valuable tools for subsequent studies on the purification and characterization of the transport protein(s) involved in serotonin uptake and may have novel behavioral and clinical effects.

Binding, Competitive↗
PubMed1982

Stereoselectivity of opiate antagonists in rat hippocampus and neocortex: responses to (+) and (-) isomers of naloxone.

The relative potencies of the (+) and (-) isomers of naloxone in antagonizing electrophysiological responses to D-alanine2-methionine enkephalinamide were compared in rat frontal cortex and hippocampus. In the in vitro hippocampus, the (-) isomer was found to be at least a 100 times more potent than the (+) isomer in antagonizing opiate-induced changes in field potentials. Similar stereoselectivity was observed in vivo in both frontal cortex and hippocampus in terms of the antagonism of enkephalin-induced changes in spontaneous cell firing. The direct effects of (+) and (-)-naloxone were examined as well. In hippocampus both in vivo and in vitro, no differential effect was observed, whereas in the neocortex (-)-naloxone was considerably more potent than the (+) isomer in eliciting depressions of spontaneous activity. These direct effects of naloxone in the cortex do not appear to be due to an antagonism of the effects of endogenously released opioids. These results demonstrate that the stereoselectivity of naloxone isomers in antagonizing electrophysiological responses to opiates in the cortex and hippocampus parallels that previously observed in other brain regions and in other tissues. In addition, they suggest that naloxone may have interactions with other unknown opiate (or possibly non-opiate) receptors which are of physiological significance.

Animals↗
PubMed1982

Beta-carbolines: synthesis and neurochemical and pharmacological actions on brain benzodiazepine receptors.

We have prepared a series of tetrahydro-beta-carbolines (TH beta C), beta-carbolines (beta-C), and other nitrogen heterocycles and evaluated them in vitro with respect to their ability to bind to benzodiazepine receptors. The fully aromatic beta-C's were more potent than their corresponding TH beta C derivatives. When substituents possessing a carbonyl (CO2Me, COCH3, CHO) were introduced at the beta-C 3-position the in vitro potency was augmented. Alcohol substituents (CH2OH, CHOHCH3) demonstrated decreased in vitro potency. The importance of the carbonyl moiety was further demonstrated when beta-carboline-3-carboxylic acid was shown to bind tighter to benzodiazepine receptors at lower pH. A lower pH increases the concentration of the acid and decreases the concentration of the anion. 3-(Hydroxymethyl)-beta-carboline (24), 3-formyl-beta-carboline (25) and 3-acetyl-beta-carboline (27) were benzodiazepine antagonists in vivo. Methyl isoquinoline-3-carboxylate (31a) also had in vitro activity. The same structure-activity relationships seen in beta-C's were also observed for isoquinolines.

Animals↗